Justices Won't Hear Challenge To Fed. Circ. Drug Patent Test
The U.S. Supreme Court said Monday it will not review a Federal Circuit decision that upheld a UCB Inc. patent on epilepsy drug Vimpat, rejecting a petition from a generic-drug maker...To view the full article, register now.
Already a subscriber? Click here to view full article